Drug Profile


Alternative Names: BIM-22493; CAM 4072; RM-493

Latest Information Update: 20 Jan 2017

Price : $50

At a glance

  • Originator Ipsen
  • Developer Charite of Berlin; Ipsen; Motus
  • Class Amides; Antihyperglycaemics; Cyclic peptides; Cysteines; Disulfides; Obesity therapies
  • Mechanism of Action Melanocortin type 4 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Prader-Willi syndrome
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Obesity
  • Phase I Diabetes mellitus

Most Recent Events

  • 01 Dec 2016 Rhythm Pharmaceuticals completes a phase II trial in Obesity in USA (SC) (NCT02311673)
  • 04 Nov 2016 Initial efficacy data from a phase II trial in Obesity (LepR deficienct) released by Rhythm Pharmaceuticals
  • 09 Sep 2016 Rhythm Pharmaceuticals plans a phase II/III trial in Obesity (In adolescents, In adults, In the elderly) in France, Germany and the United Kingdom (NCT02896192)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top